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Abstract 
Mucopolysacchatidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is the lysosomal storage disorder resulting from the deficient 
activity of N-acetylgalactosamine-4-sulfatase (arylsulfatase B; ASB). MPS VI has been described in man, cats and rats, and several 
mutations in the ASB gene have been identified in human patients and the animal models. Notably, ASB belongs to a family of sulfatases 
which are highly conserved, suggesting that they are related evolutionarily and functionally. In this manuscript, four new mutations 
causing MPS VI are described within the human ASB gene. Each of these mutations occurred in or near the hexapeptide ,,GKWHLG,,,, 
one of the most highly conserved ‘sulfatase’ regions. In fact, three of the mutations occurred within the same codon, W146. Thus, these 
results provide new insights into the molecular lesions causing MPS VI and highlight the importance of this conserved sulfatase region. 
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1. Introduction 
Mucopolysaccharidosis type VI (MPS VI; Maroteaux- 
Lamy Syndrome) is the lysosomal storage disorder result- 
ing from the deficient activity of N-acetylgalactosamine- 
4-sulfatase (arylsulfatase B; ASB; E.C. 3.1.6.12) and the 
resultant accumulation of the glycosaminoglycan (GAG), 
dermatan sulfate. The classic MPS VI phenotype includes 
course facial features, short stature, dysostosis multiplex, 
hypoflexible joints, aortic valve dysfunction, hep- 
atosplenomegaly, comeal clouding and normal intelligence 
[l]. Death usually occurs in the second or third decade of 
life. 
In addition to the human disorder, MPS VI has been 
described in cats [2] and rats [3]. Recently, the isolation 
and characterization of the human [4,5], cat [6] and rat 
[Schuchman et al., unpublished data] cDNAs encoding 
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ASB has provided the molecular tools to investigate the 
underlying genetic defects in the human disorder and the 
animal models. To date, fifteen human ASB mutations 
have been identified in MPS VI patients [g-13]. Unlike 
other mucopolysaccharidoses, each MPS VI mutation has 
been private and there is no correlation between the vari- 
able phenotype and the molecular lesions. 
ASB belongs to a family of sulfatases which hydrolyze 
sulfate esters present on various natural substrates [4,5]. 
The N-terminal regions of these sulfatases, in particular 
arylsulfatase A (ASA; sulfatide sulfatase), ASB, arylsulfa- 
tase C (ASC; steroid sulfatase) and N-acetylgalacto- 
samine-6-sulfatase (GALNS), exhibit a high degree of 
evolutionary conservation. In fact, the hexapeptide, GK- 
WHLG, is completely conserved among these sulfatases 
and believed to participate in the assembly of the ‘sulfa- 
tase’ active site [4,5]. In human ASB, the sequences 
encoding this hexapeptide are located within exon 2, from 
codons 144-149 [7]. In this communication, four new 
mutations in the ASB gene are described in or near the 
conserved GKWHLG hexapeptide. Most notably, three of 
these mutations were identified in the same codon, W146. 
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2. Materials and methods 
2.1. Patient cell lines 
The MPS VI patient cell lines were kindly provided by 
Dr. George Thomas, The Kennedy-Krieger Institute (prob- 
ands 1 and 2) and Dr. Emmanuel Shapira, Tulane Univer- 
sity (proband 3). Cell line GM00538 (proband 4) was 
obtained from the Human Genetic Mutant Cell Repository, 
Camden, NJ. Each of the probands was unrelated and had 
mild (proband 2), intermediate (proband 1) or severe 
(probands 3 and 4) forms of MPS VI. The diagnosis of 
MPS VI in the four patients was based on clinical evalua- 
tion and confirmed by the finding of markedly deficient 
ASB activity in cultured cells and/or peripheral mixed 
lymphoctyes. 
2.2. DNA sequencing 
To identify mutations in the ASB gene, genomic DNA 
was isolated by standard techniques [ 141 and direct solid- 
phase sequencing of PCR-amplified ASB genomic se- 
quences was performed as previously described [ 151. The 
complete ASB coding region, including the intron/exon 
boundaries, was amplified in eight fragments [7]. In all 
(; A T C 
cases, the antisense PCR primers were biotinylated at the 
5’ end and the PCR products were purified using Dyn- 
abeads M-280 according to the manufacturer’s instructions 
(DYNAL; Oslo, Norway). The prewashed Dynabeads were 
mixed with the PCR products (200 Kg each), incubated at 
37°C for 40 min, and collected using a Dynal MPC 
magnet. The samples were washed in 40 ~1 of ‘B&W’ 
buffer (5 mM Tris-HCl [pH 7.51, containing 0.5 mM 
EDTA and 1 M NaCl), followed by precipitation using the 
MPC magnet; 30 ~1 of 0.1 M NaOH was then added for 
10 min at room temperature and the samples were washed 
again with ‘B&W’ buffer. The immobilized single- 
stranded DNA was resuspended in 50 ~1 of TE buffer (10 
mM Tris-HCl [pH 8.01 containing 1 mM EDTA) and used 
for direct dideoxy sequencing. At least two independent 
amplification reactions were sequenced for each patient to 
confirm that the putative mutations were not due to PCR 
artifacts. 
3. Results 
DNA sequencing of the ASB genomic sequences from 
probands l-4 revealed several new mutations. Four of 
these were within exon 2, at codons 142 and 146 (Fig. I). 
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Fig. I. Identification of the M1421, W146S, W 146L and W146R mutations in MPS VI patients. Direct dideoxy DNA sequencing of ASB exon 2 was 
performed on PCR-amplified genomic DNA obtained from probands 1-4. The normal sequences of codons 142 (ATG; IA) and 146 (TGG; 1B) are 
bracketed and the mutated codons are shown to the right of each panel. Probands l-3 were heteroallelic for the M1421, Wl46S and W 146L mutations, 
respectively, while proband 4 had two mutations within the same codon (W146S and Wl46R). 
Proband 1 was heteroallelic for a G to C transversion at 
nucleotide 426 of the full-length ASB cDNA [5], resulting 
in a methionine to isoleucine substitution at codon 142 
(designated M 1421; F’ lg. IA). Surprisingly, probands 2-4 
each contained mutations within codon 146 (Fig. 1B). 
Proband 2 was heteroallelic for a G to C transversion at 
nucleotide 437, resulting in a tryptophan to serine substitu- 
tion (designated W 146s). Proband 4, an unrelated MPS VI 
patient, was heteroallelic for this mutation and a different 
point mutation within the same codon. The second muta- 
tion, designated W 146R, resulted from a T to C transition 
at nucleotide 436 and caused a tryptophan to arginine 
substitution. Proband 3 also was heteroallelic for a point 
mutation at nucleotide 436, a G to T transversion resulting 
in a tryptophan to leucine substitution at codon 146 
(Wl46L). The other ASB alleles in probands 1, 2 and 3 
carried mutations that were located outside the conserved 
hexapeptide region (not shown). 
Thus. each of the four mutations described in this 
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manuscript occurred within a small highly conserved re- 
gion of exon 2. In fact, three mutations occurred within the 
same codon (W 146L, W 146R and W 146s). Moreover, 
Wl46S was found in two unrelated patients (probands 2 
and 4), the first example of a non-private mutation in this 
disorder. Two possible explanations might account for 
these findings. This region may be a ‘genetic hot-spot’ 
which is susceptible to molecular lesions or a ‘functional 
hot-spot’ which is critical for ASB structure and/or func- 
tion. Since none of the mutations occurred at a CpG 
dinucleotide and all were within a highly conserved pep- 
tide sequence, the latter explanation is more likely. 
4. Discussion 
The hexapeptide GKWHLG has been conserved in 
sulfatases from bacteria through man (Fig. 2) and the GK 
dipeptide within this region is conserved among all known 
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Fig. 2. Mutations in the ASB gene causing MPS VI and conservation of amino acid sequences among different sulfatases. (A) The genomic organization of 
the human ASB gene [7] and the location of mutations causing MPS VI. Note that of the 19 known mutations, 10 occur within a small region of exon 2. In 
fact, 9 of these exon 2 mutations are in a 23 amino acid region which includes the hexapeptide GKWHLG. (B) An amino acid comparison of several 
different sulfatases, including human ASB, ASA, ASC and GALNS, cat and rat ASB, mouse ASA, an arylsulfatase from the sea urchin (designated SUAS) 
and a bacteri$ sulfatase from K. nerogenes. Note the complete conservation of the hexapeptide sequence among these different sulfatases. The location of 
the codon 142 and 146 mutations are shown along with the two other previously reported mutations [8- 131 within this I5 amino acid region (G I37V and 
G 144R). 
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human sulfatases, including iduronate 2-sulfatase and glu- 
cosamine-6-sulfatase [16]. In addition to the three codon 
146 mutations described here, a mutation within codon 144 
(G144R) of the ASB hexapeptide has been previously 
reported [ 121. Moreover, several other MPS VI mutations 
(including M1421) are nearby. The high degree of homol- 
ogy within this region and the fact that many of the 
mutations causing MPS VI, Hunter syndrome (MPS II) 
and metachromatic leukodystrophy occur in or near it, 
suggests that it plays a critical role in ASB and other 
sulfatase activities. For example, in a severe MPS II 
patient, a mutation in the iduronate-2-sulfatase gene has 
been identified in codon 135 (K135R), which is located 
within this conserved hexapeptide [ 171. Furthermore, in 
metachromatic leukodystrophy, a point mutation (G122S) 
occurs within this region of the arylsulfatase A gene [18]. 
This glycine codon is homologous to the G144 codon in 
the ASB gene. 
Thus, investigations into the molecular lesions underly- 
ing MPS VI and other sulfatase deficiency disorders has 
provided intriguing insights into this enzyme family. Fu- 
ture studies will include overexpression and purification of 
these enzymes for structural analysis and site-directed 
mutagenesis of the conserved regions for biochemical 
comparison. In addition, new mutations will continue to be 
identified, providing insights into the the structure and 
function of these enzymes and the molecular tools to 
diagnose patients with the deficiency disorders. 
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